Evidence map›Paper›PMID 34556065›Full record

ArticleBMC public health2021

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.

Claire von Mollendorf, Mukhchuluun Ulziibayar, Bradford D Gessner, Lien Anh Ha Do, Cattram D Nguyen, Rohini Beavon, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Adam Jenney and 5 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Microbiology spectrum · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Claire von MollendorfInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia. claire.vonmollendorf@mcri.edu.au.ORCID 0000-0003-0927-1731
Mukhchuluun UlziibayarNational Center for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Bradford D GessnerPfizer Vaccines, Collegeville, PA, USA.
Lien Anh Ha DoInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Cattram D NguyenInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Rohini BeavonPfizer Vaccines, Tadworth, Surrey, UK.
Bujinlkham SuuriNational Center for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Dashtseren LuvsantserenNational Center for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Dorj NarangerelMinistry of Health, Ulaanbaatar, Mongolia.
Adam JenneyInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Eileen M DunneInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Catherine SatzkeInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Badarchiin DarmaaNational Center for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
Tuya MungunNational Center for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia.
E Kim MulhollandInfection and Immunity, New Vaccines Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia.
Royal Children's Hospital · AUNational Center for Communicable Diseases · MNMinistry of Health · MNPfizer (United Kingdom) · GBPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommunity-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colonisation with vaccine-type serotypes. The resulting decrease in transmission of vaccine serotypes leads to large indirect effects. There are limited data from developing countries demonstrating the impact of childhood PCV immunisation on adult pneumonia. There are also insufficient data available on the burden and severity of all-cause pneumonia and respiratory syncytial virus (RSV) in adults from low resource countries. There is currently no recommendation for adult pneumococcal vaccination with either pneumococcal polysaccharide vaccine or PCVs in Mongolia. We describe the protocol developed to evaluate the association between childhood 13-valent PCV (PCV13) vaccination and trends in adult pneumonia.

methodsPCV13 was introduced into the routine childhood immunisation schedule in Mongolia in a phased manner from 2016. In March 2019 we initiated active hospital-based surveillance for adult pneumonia, with the primary objective of evaluating trends in severe hospitalised clinical pneumonia incidence in adults 18 years and older in four districts of Ulaanbaatar. Secondary objectives include measuring the association between PCV13 introduction and trends in all clinically-defined pneumonia, radiologically-confirmed pneumonia, nasopharyngeal carriage of S. pneumoniae and pneumonia associated with RSV or influenza. Clinical questionnaires, nasopharyngeal swabs, urine samples and chest radiographs were collected from enrolled patients. Retrospective administrative and clinical data were collected for all respiratory disease-related admissions from January 2015 to February 2019. DISCUSSION: Establishing a robust adult surveillance system may be an important component of monitoring the indirect impact of PCVs within a country. Monitoring indirect impact of childhood PCV13 vaccination on adult pneumonia provides additional data on the full public health impact of the vaccine, which has implications for vaccine efficiency and cost-effectiveness. Adult surveillance in Mongolia will contribute to the limited evidence available on the burden of pneumococcal pneumonia among adults in low- and middle-income countries, particularly in the Asia-Pacific region. In addition, it is one of the few examples of implementing prospective, population-based pneumonia surveillance to evaluate the indirect impact of PCVs in a resource-limited setting.

Indexed as

Pneumococcal InfectionsPneumonia, PneumococcalAdultHumansMongoliaObservational Studies as TopicPneumococcal VaccinesProspective StudiesRetrospective StudiesVaccines, ConjugatePneumococcal VaccinesVaccines, ConjugateAdult pneumoniaIndirect PCV impactMongoliaNasopharyngeal carriagePneumococcal conjugate vaccineStreptococcus pneumoniaeSurveillance

Identifiers

PMID34556065
PMCPMC8460191
OpenAlexW3199347472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.